Tareeva I E, Kutyrina I M, Neverov N I
Klin Med (Mosk). 1995;73(3):80-3.
Inhibition of non-immune progression of renal insufficiency for control of glomerulonephritis was attempted via hemodynamic, metabolic and hypolipidemic means. Hemodynamic correction was conducted using inhibitors of angiotensin-converting enzyme capoten and renitek. The action on metabolic factors of progression was realized by lovastatin mevakor. Capoten and renitek exhibited in 57 patients with chronic nephritis not only a hypotensive effect, but also reduced intraglomerular hypertension and proteinuria. A long-term (7-12 months) hypolipidemic therapy (diet and lovastatin) in 20 patients with chronic glomerulonephritis with nephrotic syndrome resulted in lowering of serum cholesterol concentrations and proteinuria, raised serum albumin. 9 patients achieved remission of nephrotic syndrome. The highest effect occurred in non-inflammatory nephropathy: membranous nephropathy, focal-segmental glomerulosclerosis, nephrosclerosis.
尝试通过血流动力学、代谢和降血脂手段抑制肾功能不全的非免疫性进展以控制肾小球肾炎。使用血管紧张素转换酶抑制剂卡托普利和雷米普利进行血流动力学纠正。洛伐他汀（美降脂）实现了对进展代谢因素的作用。卡托普利和雷米普利在57例慢性肾炎患者中不仅表现出降压作用，还降低了肾小球内高血压和蛋白尿。对20例患有肾病综合征的慢性肾小球肾炎患者进行长期（7 - 12个月）的降血脂治疗（饮食和洛伐他汀），导致血清胆固醇浓度降低、蛋白尿减少、血清白蛋白升高。9例患者肾病综合征缓解。最高疗效出现在非炎性肾病：膜性肾病、局灶节段性肾小球硬化、肾硬化。
